Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
Journal
Lancet (London, England)
Journal Volume
392
Journal Issue
10163
Pages
2441
Date Issued
2018-12-08
Author(s)
van der Heijde, Désirée
Cheng-Chung Wei, James
Dougados, Maxime
Mease, Philip
Deodhar, Atul
Maksymowych, Walter P
Van den Bosch, Filip
Sieper, Joachim
Tomita, Tetsuya
Landewé, Robert
Zhao, Fangyi
Krishnan, Eswar
Adams, David H
Pangallo, Beth
Carlier, Hilde
Abstract
Biological disease-modifying anti-rheumatic drugs (bDMARDs) are recommended for radiographic axial spondyloarthritis, otherwise known as ankylosing spondylitis, when conventional therapies are not effective. We report efficacy and safety data on ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A (IL-17A), in patients with radiographic axial spondyloarthritis who have not previously been treated with bDMARDs.
SDGs
Type
journal article